Skip to main content
. 2022 May 13:10.1111/hae.14586. Online ahead of print. doi: 10.1111/hae.14586

TABLE 2.

Primary and secondary endpoints (part A)

Endpoint Patients n / N Proportion in percentage (95% CI) a
Injection site bleeding 7 / 461 1.5 (.7‐3.1)
Other injection site reactions 12 / 461 2.6 (1.5‐4.5)
Fever ≥38.5°C 26 / 461 5.6 (3.9‐8.1)
Other 39 / 461 8.5 (6.3‐11.4)
a

Wilson 95% confidence interval.